Smith & Nephew SNATS, Inc. (NYSE:SNN) Shares Bought by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. boosted its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 8.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,923 shares of the medical equipment provider’s stock after buying an additional 803 shares during the period. PNC Financial Services Group Inc.’s holdings in Smith & Nephew SNATS were worth $282,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SNN. Hara Capital LLC boosted its stake in Smith & Nephew SNATS by 391.4% during the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 1,957 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Smith & Nephew SNATS during the fourth quarter worth $4,992,000. Sterling Capital Management LLC acquired a new position in shares of Smith & Nephew SNATS in the 4th quarter valued at $265,000. Townsquare Capital LLC lifted its stake in shares of Smith & Nephew SNATS by 19.0% in the 4th quarter. Townsquare Capital LLC now owns 17,557 shares of the medical equipment provider’s stock valued at $432,000 after purchasing an additional 2,798 shares during the last quarter. Finally, Barclays PLC acquired a new position in shares of Smith & Nephew SNATS in the 4th quarter valued at $431,000. Institutional investors and hedge funds own 25.64% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on SNN shares. Hsbc Global Res lowered Smith & Nephew SNATS from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th. Canaccord Genuity Group upped their price target on Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a “hold” rating in a research note on Thursday, May 1st. Finally, HSBC lowered Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Friday, April 25th. Six investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.00.

Smith & Nephew SNATS Price Performance

Shares of NYSE SNN opened at $36.20 on Friday. The stock’s 50-day moving average is $31.24 and its two-hundred day moving average is $28.84. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. Smith & Nephew SNATS, Inc. has a 1-year low of $23.69 and a 1-year high of $36.84. The company has a market cap of $15.85 billion, a price-to-earnings ratio of 16.76, a price-to-earnings-growth ratio of 1.00 and a beta of 0.68.

Smith & Nephew SNATS Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 3rd will be issued a dividend of $0.285 per share. The ex-dividend date is Friday, October 3rd. This represents a yield of 210.0%. Smith & Nephew SNATS’s dividend payout ratio is 26.39%.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.